. On the other hand, we have revealed that repeated stress induces synaptic depression by increasing the ubiquitin/ proteasome-mediated degradation of NMDAR and AMPAR subunits, resulting in impaired recognition memory (Yuen et al., 2012, Neuron). Moreover, females and males show different cognitive and emotional responses to repeated stress and estrogen prevents the detrimental effects of repeated stress on glutamatergic transmission and cognition (Wei et al., 2014, Mol. Psychiatry). Currently, we have found that an epigenetic mechanism involving histone modifications can be used as a potential rescue strategy for the detrimental effects of chronic stress.
Speaker 4: Maurizio Popoli, Italy
Title: Stress and drugs in the brain. Timedependent changes in synaptic function and brain architecture Abstract Stressful life events represent major risk factors for the development of neuropsychiatric disorders, such as mood and anxiety disorders, which account for a large share of mental health issues worldwide and represent a great therapeutic challenge. In vulnerable individuals, repeated stress or single major stressful events induce brain alterations, which involve synaptic transmission and morphology in the glutamate (Glu) system, ultimately impairing brain functions related to cognition, emotions and homeostatic mechanisms [1, 2] .
A wealth of neuroimaging studies have shown volumetric reduction and remodeling of neuroarchitecture in limbic/cortical brain areas of depressed subjects; at the same time chronic stress models in rodents have consistently shown reduction of synaptic spines and atrophy/remodeling of dendrites in the same areas affected in humans, thus suggesting that stressinduced maladaptive changes have a primary role in the chain of events leading to development of psychopathology. Instead, the rapid effects of acute stress on synaptic function/plasticity are often opposite, with enhancement of glutamate release/ transmission, increased number of spines/synapses, enhancement of synaptic strength. The somewhat opposite modifications of acute vs chronic stress suggest a bi-phasic process, during which, at some unknown points, the stress response turns from increased excitatory activation into its opposite [3] [4] . However, while the effects of chronic stress have been investigated at length in animal models, the short-and long-term consequences of acute stressors have been little or not investigated, although it has been shown that in some cases (e.g., PTSD) the first few hours after trauma are crucial for pathophysiological outcome and therapeutic intervention [5] .
We have shown previously that acute inescapable stress rapidly enhances glutamate release/transmission in prefrontal/ frontal cortex (PFC/FC), by synaptic corticosterone (CORT) receptors-dependent non-genomic increase of readily releasable pool (RRP) of vesicles in perforated synapses [6] . Recently, we started investigating the medium-and long-term changes induced by acute stress, with the aim of looking at key determinants in the outcome of stress. Surprisingly, by using EM-stereology, we found that after 40 min of inescapable stress, the enhancement of glutamate release/transmission in PFC was accompanied by a dramatic increase (42,6%) of total number of excitatory synapses (due to non-perforated and axo-spinous synapses), an effect prevented by antidepressant treatment [8] . Spine density was elevated up to 24 h but returned to normal level later; instead dendritic arborization was already reduced 24 h after stress [9] . While confirming a bi-phasic mode in the outcome of acute stress, these results showed for the first time that a single exposure to stress can exert complex and remarkable effects on PFC architecture, both rapid and sustained in time.
Abstracts | 39 Abstract Oxytocin has been proposed as a potential treatment approach in drug addiction, but little is known about the effects of oxytocin in translationally relevant models of addiction or the neurobiological substrates of the actions of oxytocin. This presentation highlights the ability of oxytocin to reduce drug taking and drug seeking in a rat model of methamphetamine (meth) addiction.
In the first set of experiments, we developed and applied a behavioral economics model of meth addiction to assess the effects of oxytocin on both meth demand and conditioned cueinduced reinstatement of meth seeking following a period of drug withdrawal. Systemic oxytocin treatment reduced both meth demand (determined by an increase in α, the downward acceleration of a demand curve) and reinstatement of cueinduced meth seeking. Notably, oxytocin had the highest efficacy to reduce reinstatement in those rats showing the highest motivation for meth.
A second set of experiments examined the central effects of oxytocin on meth demand and reinstatement. The effects of systemic oxytocin on meth demand were completely blocked by central infusion (icv) of an oxytocin receptor antagonist, while direct application of oxytocin in the nucleus accumbens (NAc) abolished the effects of oxytocin on both meth demand and reinstatement. Finally, oxytocin activity in the NAc was found to be necessary for enhanced meth demand, as central antagonism of oxytocin receptors in the NAc blocked the effects of systemic oxytocin.
Taken together, these results show a centrally mediated action of oxytocin in reducing demand for meth and cueinduced reinstatement of meth seeking. Future development of oxytocin-based pharmacotherapy may be beneficial for psychostimulant addiction.
Speaker 2: Inga D Neumann, Germany
Title: Chronic effects of oxytocin: Are we ready for its therapeutic use? Abstract Due to its acute pro-social and anxiolytic properties, and the attenuation of stress responses the neuropeptide OXT has received substantial interest. We have recently shown that OXT promotes social preference behaviour and prevents social phobia induced by social defeat stress in rats and mice 1 . Further, in a mouse paradigm for social fear conditioning 2 , OXT specifically reversed social fear -an effect which was localized within the dorsolateral septum, where social fear was associated with reduced OXT receptor binding 3 . In contrast to its acute effects, chronic central OXT infusion over 14 days using osmotic minipumps dose-dependently increased anxiety of male mice and reduced OXT receptor binding in the basolateral amygdala, nucleus raphe and dorsolateral septum. At lower dose, continuous chronic infusion of OXT was able to prevent a variety of chronic stress-induced mal-adaptations. We are currently studying the consequences of chronic OXT on OXT receptor-coupled intracellular signaling pathways in males and females.
Although the acute effects point towards the therapeutic use of OXT for anxiety-related disorders including social phobia more detailed behavioral and molecular studies are needed to reveal chronic effects.
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